处方药市场战略、主要参与者、增长机会、2031 年分析和预测

  • Report Code : TIPRE00040966
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 315
立即购买

处方药市场规模预计将从2024年的1.44079万亿美元增至2031年的2.35012万亿美元。预计2025年至2031年期间,该市场的复合年增长率将达到7.3%。个性化医疗和精准医疗的增长可能会在未来几年为处方药市场带来新的趋势。

处方药市场分析

慢性病患病率的不断上升,以及创新药物和专科药物的不断开发和应用,推动了处方药市场的发展。此外,人们对各种疾病的认识不断提高,以及新药的开发,预计将在不久的将来促进市场增长。此外,新产品的开发、上市、审批和扩张预计将在未来几年创造充足的机会。

处方药市场概况

预计在预测期内,北美将占据处方药市场的主导地位,占据最大份额。此外,由于人口老龄化,预计亚太地区也将出现显著的复合年增长率,这增加了对慢性病管理和长期用药的需求。随着生活方式相关疾病发病率的上升,对有效处方药的需求激增。此外,印度、中国和东南亚国家等发展中国家医疗基础设施的改善和医疗机构可​​及性的提高,扩大了处方药的覆盖范围,使以前服务不足的人群也能获得处方药。可支配收入的增加和中产阶级人口的扩大提高了人们在医疗保健(包括处方药)上的负担能力和支出意愿。亚太地区各国政府已将医疗改革和增加医疗支出列为优先事项,鼓励更好的保险覆盖和报销政策,以支持药品消费。

技术进步和药物研发的增长推动了靶向治疗的创新,吸引了更多患者和医生使用处方药。人们对现代医疗保健实践的认识和接受度不断提高,加上城镇化和生活方式的改变,进一步推动了处方药需求的增长。此外,数字健康平台和远程医疗的兴起改善了患者获得医疗服务的机会,促进了更好的诊断和处方依从性。

定制此报告以满足您的要求

您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣

处方药市场:

Prescription Drugs Market
  • 获取此报告的顶级关键市场趋势。
    此免费样品将包括数据分析,从市场趋势到估计和预测。

处方药市场驱动因素和机遇

慢性疾病患病率不断上升

人口老龄化加剧和生活方式的改变导致了一些常见的长期健康状况。根据世界卫生组织 (WHO) 的预测,到 2026 年底,慢性生活方式疾病的患病率预计将增加 57%。随着城市化进程的加快,人们越来越倾向于久坐不动的生活方式,这导致了类风湿性关节炎、糖尿病和其他疾病的发生。糖尿病是 21 世纪全球主要的健康问题之一。根据国际糖尿病联合会 (IDF) 的数据,2024 年全球有 5.89 亿成年人患有糖尿病,预计到 2050 年底将达到 8.53 亿。预测期内,疾病患病率预计将增加 35%。

其他慢性疾病,例如多发性硬化症、克罗恩氏病、神经系统疾病和心血管疾病,需要各种药物进行长期管理。根据世界卫生组织的数据,心血管疾病是主要的死亡原因之一,每年导致全球 1790 万人死亡。此外,慢性疾病的性质往往需要使用多种药物和先进的疗法,包括凭处方出售的生物制剂和特种药物,这些药物通常价格更高,为制药公司带来更高的收入。此外,罕见病患者未满足的临床需求刺激了新疗法的开发,导致大型制药公司增加对研发的投资。因此,慢性病患病率的上升和未满足的临床需求推动了处方药市场的发展。

市场参与者的战略举措为市场增长创造了充足的机会

处方药市场中的各类参与者都专注于产品审批、上市和战略合作,以开发治疗和管理慢性疾病所需的有效产品。因此,处方药市场近期出现了一些新进展。以下列举其中几项:

  • 2025年5月,百奥泰公司(Bio-Thera Solutions, Ltd.)的Starjemza注射液获得FDA批准。该注射液是一种人白细胞介素-12和-23拮抗剂,可与Stelara互换生物类似药,用于治疗克罗恩病、斑块状银屑病、溃疡性结肠炎和银屑病关节炎。
  • 2024年11月,阳光生物制药公司(Sunshine Biopharma Inc.)推出了一款名为熊去氧胆酸(Ursodiol)的新型仿制药,该药物又名熊去氧胆酸(UDCA)。该药物用于治疗胆汁淤积性肝病,包括原发性胆汁性肝硬化(PBC)。
  • 2024年6月,梯瓦公司(Teva)在美国上市了Victoza(利拉鲁肽注射液1.8毫克)的授权仿制药。该药物用于改善10岁及以上2型糖尿病成人和儿童患者的血糖控制,并降低2型糖尿病患者发生心血管事件的风险。
  • 2024 年 4 月,ImmunityBio, Inc. 获得 FDA 批准,可使用 ANKTIVA 联合卡介苗 (BCG) 治疗对 BCG 无反应且伴有原位癌 (CIS) 的非肌层浸润性膀胱癌 (NMIBC) 患者,无论是否伴有乳头状肿瘤。
  • 2022年10月,辉瑞公司完成对Biohaven制药控股有限公司的收购,增加了包括NURTEC ODT在内的突破性降钙素基因相关肽产品组合,以满足全球偏头痛患者的需求。
  • 2022年1月,Cosette Pharmaceuticals从第一三共株式会社及其附属公司手中收购了八种处方药在美国的销售和分销权。这些产品包括Benicar、Benicar HCT、Azor、Tribenzor、Welchol、Welchol口服混悬液、Effient和Evoxac。

因此,预计未来几年产品发布、批准和战略合作的增加将为处方药市场的增长创造充足的机会。

处方药市场报告细分分析

处方药市场分析的基础关键部分是产品类型、药物类型、给药途径、治疗领域和分销渠道。

  • 根据产品类型,处方药市场分为品牌药和仿制药。品牌细分市场在 2024 年占据了更大的市场份额,预计在 2025-2031 年期间将实现更高的复合年增长率。
  • 按药物类型划分,处方药市场分为小分子药物、生物制剂和生物仿制药。2024年,小分子药物占据了更大的市场份额。预计在2025年至2031年期间,生物制剂和生物仿制药的复合年增长率将更高。
  • 就治疗领域而言,处方药市场细分为肿瘤科、心血管疾病、神经系统疾病、代谢性疾病、呼吸系统疾病、免疫学及其他领域。肿瘤科领域在2024年占据市场主导地位,预计在2025年至2031年期间将实现最高的复合年增长率。
  • 根据给药途径,处方药市场可分为口服、注射、外用和其他。口服药物在2024年占据了最大的市场份额,预计在2025年至2031年期间将实现最高的复合年增长率。
  • 就分销渠道而言,处方药市场细分为医院药房、零售药房和在线药房。医院药房在2024年占据市场主导地位,预计在2025年至2031年期间将实现最高的复合年增长率。

处方药市场份额按地区分析

处方药市场报告的地理范围主要分为五个区域:北美、亚太地区、欧洲、中东和非洲以及南美和中美。北美在2024年占据了相当大的市场份额。人口老龄化是北美处方药市场发展的驱动力。随着婴儿潮一代年龄的增长,糖尿病、心血管疾病和癌症等慢性病的患病率也在上升,从而刺激了处方药的需求。

药物研究和生物技术的进步也发挥了关键作用。包括生物制剂和个性化医疗在内的药物开发创新拓展了治疗选择,提高了疗效和安全性。针对此前无法治愈的疾病的新型疗法的引入推动了市场的增长。

另一个主要因素是北美强大的医疗基础设施,这得益于对医疗机构、保险覆盖和药品分销网络的大量投资。医疗服务的普及以及患者疾病管理意识的提高,增加了处方药的消费。此外,美国食品药品监督管理局 (FDA) 等机构的监管支持加快了创新药物的审批流程,使其能够更快地进入市场。此外,旨在扩大医疗保险覆盖范围的政府举措,例如美国的《平价医疗法案》,也增加了更广泛人群获得处方药的机会。

此外,生活方式相关疾病的增多以及精神健康障碍的患病率上升,也导致了对治疗药物的持续需求。新冠疫情也凸显了药物干预的重要性,加速了对药物研发和分销的投资。

 

处方药市场区域洞察

Insight Partners 的分析师已详尽阐述了预测期内影响处方药市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的处方药市场细分和地域分布。

Prescription Drugs Market
  • 获取处方药市场的区域特定数据

处方药市场报告范围

报告属性细节
2024年的市场规模14407.9亿美元
2031年的市场规模23501.2亿美元
全球复合年增长率(2025-2031)7.3%
史料2021-2023
预测期2025-2031
涵盖的领域按产品类型
  • 品牌
  • 泛型
按类型
  • 小分子
  • 生物制剂和生物仿制药
按治疗领域
  • 肿瘤学
  • 心血管疾病
  • 神经系统疾病
  • 代谢性疾病
  • 呼吸系统疾病
  • 免疫学
  • 其他的
按给药途径
  • 口服
  • 注射剂
  • 外用
  • 其他的
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 韩国
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  • 强生公司
  • 辉瑞公司
  • 默克公司
  • 礼来公司
  • 埃斯蒂夫
  • 阿斯利康公司
  • 赛诺菲公司
  • 葛兰素史克公司
  • F. 霍夫曼-拉罗氏
  • 诺华公司

 

处方药市场参与者密度:了解其对业务动态的影响

处方药市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求的驱动因素包括消费者偏好的演变、技术进步以及对产品益处的认知度的提升。随着需求的增长,企业正在扩展产品线,不断创新以满足消费者需求,并抓住新兴趋势,从而进一步推动市场增长。

市场参与者密度是指特定市场或行业内企业或公司的分布情况。它表明特定市场空间内竞争对手(市场参与者)的数量相对于其规模或总市值而言。

在处方药市场运营的主要公司有:

  1. 强生公司
  2. 辉瑞公司
  3. 默克公司
  4. 礼来公司
  5. 埃斯蒂夫
  6. 阿斯利康公司

免责声明以上列出的公司没有按照任何特定顺序排列。


Prescription Drugs Market

 

  • 获取处方药市场顶级关键参与者概述

处方药市场新闻和最新发展

处方药市场评估是通过收集一手和二手研究后的定性和定量数据进行的,这些数据包括重要的公司出版物、协会数据和数据库。以下列出了市场的一些发展情况:

  • ESTEVE 计划在其位于赫罗纳的 Celrà 工业中心投资 1 亿欧元新建一座制造工厂,预计于 2026 年竣工。此次扩建将提升活性药物成分的生产能力,并新增约 100 个工作岗位,使员工总数增至约 470 人。该项目包括新建生产和服务大楼,并安装 150 立方米的反应容积,这将使 Celrà 的生产能力提升 45%,公司整体产能提升 15%。(来源:ESTEVE,公司网站,2025 年 6 月)
  • 罗氏公司将在未来五年内在美国投资500亿美元。这些投资将进一步增强罗氏在美国的影响力。目前,罗氏旗下制药和诊断部门在美国拥有13个制造基地和15个研发基地,预计将创造超过12,000个新就业岗位,其中包括约6,500个建筑岗位,以及新建和扩建工厂带来的1,000个就业岗位。(来源:F. Hoffmann-La Roche Ltd,公司网站,2025年4月)
  • 辉瑞公司已获得美国食品药品监督管理局 (FDA) 批准 ADCETRIS (brentuximab vedotin) 联合来那度胺和利妥昔单抗产品的补充生物制剂许可申请 (sBLA)。该疗法适用于已接受两线或两线以上全身治疗的复发或难治性大 B 细胞淋巴瘤 (LBCL) 成人患者,包括各种类型的弥漫大 B 细胞淋巴瘤 (DLBCL)。该疗法适用于不适合接受自体造血干细胞移植 (auto-HSCT) 或嵌合抗原受体 T 细胞疗法的患者。(来源:辉瑞公司,公司网站,2025 年 2 月)

处方药市场报告覆盖范围和交付成果

《处方药市场规模和预测(2021-2031)》报告对以下领域进行了详细的市场分析:

  • 处方药市场规模以及涵盖范围内所有主要市场领域的全球、区域和国家层面的预测
  • 处方药市场趋势以及市场动态,例如驱动因素、限制因素和关键机遇
  • 详细的 PEST 和 SWOT 分析
  • 处方药市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
  • 行业格局和竞争分析,涵盖市场集中度、热图分析、知名参与者以及处方药市场的最新发展
  • 详细的公司简介
  • 历史分析(2 年)、基准年、预测(7 年)及复合年增长率
  • PEST 和 SWOT 分析
  • 市场规模价值/数量 - 全球、区域、国家
  • 行业和竞争格局
  • Excel 数据集
prescription-drugs-market-report-deliverables-img1
prescription-drugs-market-report-deliverables-img2
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

常见问题


What is the expected CAGR of the prescription drugs market?

The prescription drugs market is estimated to register a CAGR of 7.3% during the forecast period.

What would be the estimated value of the prescription drugs market by 2031?

The prescription drugs market is estimated to reach a value of US$ 2,350.12 billion by 2031.

Which are the leading players operating in the prescription drugs market?

Johnson & Johnson; Pfizer Inc; Merck & Co Inc; Eli Lilly and Co; ESTEVE; AstraZeneca Plc; Sanofi SA; GSK Plc; F. Hoffmann-La Roche; Novartis AG; AbbVie Inc; Teva Pharmaceutical Industries Ltd are among the key players operating in the prescription drugs market.

Which region dominated the prescription drugs market in 2024?

North America dominated the market in 2024.

What are the factors driving the prescription drugs market?

The increasing prevalence of chronic disorders and the increasing development and adoption of innovative and specialty drugs are the most influential factors responsible for the market growth.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - Prescription Drugs Market

  1. Johnson & Johnson
  2. Pfizer Inc
  3. Merck & Co Inc
  4. Eli Lilly and Co
  5. ESTEVE
  6. AstraZeneca Plc
  7. Sanofi SA
  8. GSK Plc
  9. F. Hoffmann-La Roche
  10. Novartis AG
  11. AbbVie Inc
  12. Teva Pharmaceutical Industries Ltd
prescription-drugs-market-cagr

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.